-

08:28:15 AM

PRFX Stock News

PRFX - PainReform Ltd

03/28/23 9:10 AM

Nasdaq : PRFX

clinical triallow float

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

PainReform Ltd. (Nasdaq: PRFX) (" PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today

RHEA-AI

neutral

03/16/23 8:00 AM

Nasdaq : PRFX

clinical triallow float

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2022.

RHEA-AI

positive

03/14/23 8:00 AM

Nasdaq : PRFX

clinical triallow float

PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery

PainReform Ltd. (Nasdaq: PRFX) (" PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics,

RHEA-AI

neutral

02/07/23 4:05 PM

Nasdaq : PRFX

low float

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement

PainReform Ltd. (Nasdaq: PRFX) (" PainReform" or the " Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announced today that on February 7, 2023, it received a letter from The

RHEA-AI

neutral

11/15/22 8:30 AM

Nasdaq : PRFX

low float

PainReform Provides Business Update for the Third Quarter of 2022

PainReform Ltd. (Nasdaq: PRFX) (" PainReform" or the " Company"), a clinical-stage specialty pharmaceutical

RHEA-AI

neutral

11/08/22 8:30 AM

Nasdaq : PRFX

low float

PainReform Provides Further Update on Manufacturing of PRF-110

PainReform Ltd. (Nasdaq: PRFX) (" PainReform" or the " Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a further update related to the manufacturing process of

RHEA-AI

very positive

10/04/22 9:00 AM

Nasdaq : PRFX

low float

PainReform Provides PRF-110 Manufacturing Update

PainReform Ltd. (Nasdaq: PRFX) (" PainReform" or the " Company"), a clinical-stage specialty

RHEA-AI

very positive

09/01/22 8:00 AM

Nasdaq : PRFX

conferenceslow float

PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PainReform Ltd. (Nasdaq: PRFX) (" PainReform" or the " Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of

RHEA-AI

neutral

08/16/22 8:05 AM

Nasdaq : PRFX

low float

PainReform Provides Business Update for the Second Quarter of 2022

PainReform Ltd. (Nasdaq: PRFX) (" PainReform" or the " Company"), a clinical-stage

RHEA-AI

positive

08/16/22 8:00 AM

Nasdaq : PRFX

low float

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

PainReform Ltd. (Nasdaq: PRFX) (“ PainReform ” or the “ Company ”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from the Nasdaq

RHEA-AI

neutral

PRFX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.painreform.com
Security namePainReform Ltd
Issue typecs
SectorManufacturing
Sic code2834
Employees4
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Medicinal and Botanical Manufacturing

About PainReform Ltd

PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The Company's proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.